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Abstract 
Rationale: Epstein-Barr virus (EBV) is the causative pathogen for infectious mononucleosis and many 
kinds of malignancies including several lymphomas such as Hodgkin's lymphoma, Burkitt's lymphoma and 
NK/T cell lymphoma as well as carcinomas such as nasopharyngeal carcinoma (NPC) and EBV-associated 
gastric carcinoma (EBV-GC). However, to date no available prophylactic vaccine was launched to the 
market for clinical use. 
Methods: To develop a novel vaccine candidate to prevent EBV infection and diseases, we designed 
chimeric virus-like particles (VLPs) based on the hepatitis B core antigen (HBc149). Various VLPs were 
engineered to present combinations of three peptides derived from the receptor binding domain of EBV 
gp350. All the chimeric virus-like particles were injected into Balb/C mice for immunogenicity evaluation. 
Neutralizing titer of mice sera were detected using an in vitro cell model. 
Results: All chimeric HBc149 proteins self-assembled into VLPs with gp350 epitopes displayed on the 
surface of spherical particles. Interestingly, the different orders of the three epitopes in the chimeric 
proteins induced different immune responses in mice. Two constructs (149-3A and 149-3B) induced high 
serum titer against the receptor-binding domain of gp350. Most importantly, these two VLPs elicited 
neutralizing antibodies in immunized mice, which efficiently blocked EBV infection in cell culture. 
Competition analysis showed that sera from these mice contained antibodies to a major neutralizing 
epitope recognized by the strong neutralizing mAb 72A1.  
Conclusion: Our data demonstrate that HBc149 chimeric VLPs provide a valuable platform to present 
EBV gp350 antigens and offer a robust basis for the development of peptide-based candidate vaccines 
against EBV. 
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Epstein-Barr virus (EBV), a widespread human 
γ-herpesvirus, causes persistent infection in more 
than 95% of the world population [1, 2]. Primary EBV 
infection is usually asymptomatic and often occurs 
during childhood. EBV is the major cause of infectious 
mononucleosis (IM) and is also tightly linked to 
various malignancies including Hodgkin's lymphoma 
(HL), Burkitt's lymphoma (BL), NK/T cell lymphoma, 
nasopharyngeal carcinoma (NPC) and gastric 
carcinoma (GC) [3]. Immunocompromised indivi-
duals such as transplant recipients and AIDS patients 
are at increased risk of developing EBV-associated 
malignancies [4-7]. 
It is urgent to develop an effective vaccine to 
prevent EBV infection [8, 9]. However, to date, there is 
no approved vaccine against EBV infection and 
EBV-associated diseases. EBV encodes many envelope 
glycoproteins. The most abundant glycoprotein on the 
virion surface, gp350 has been one of the most studied 
targets for development of a prophylactic subunit 
vaccine to neutralize infection of B cells. In response 
to natural EBV infection, gp350 is the major 
immunogen to induce a neutralizing antibody 
response in human sera, which protects B cells against 
infection [10, 11]. Immunization with antigens 
comprising glycoproteins from the viral fusion 
apparatus (gH/gL, gH/gL/gp42 and gB) have 
elicited robust antibody response that have the 
advantage of neutralizing infection of B cells as well 
as epithelial cells [12-15] . Thus, the fusion apparatus 
glycoproteins have become components of choice in 
the design of prophylactic vaccines. Finally, 
antibodies against EBV BMRF2 prevented virus 
attachment and and entry into epithelial cells [16]. The 
need for efficient protection of the two EBV target cell 
types in vivo, B cells and epithelial cells, will likely 
require immunization with combinations of viral 
glycoprotein antigens using common platform such as 
nanoparticles or VLPs. Recombinant gp350/220 
proteins expressed in E.coli and insect cells were used 
to define the region reacting with the virus capsid 
antigen (VCA)-positive human sera [17]. MAbs 
against gp350/220 showed neutralizing activity to 
prevent EBV infection [18, 19]. A representative 
mouse monoclonal antibody (mAb) 72A1, effectively 
blocked EBV infection of B cells [20, 21]. Moreover, 
mAb 72A1 directly bound to an epitope on the 
glycan-free surface which was identified as the 
receptor binding domain (RBD) of gp350 [22, 23]. The 
interaction between gp350 and the complement 
receptor type2 (CR2/CD21) on B lymphocytes is 
needed to trigger infection. The RBD is located at the 
N-terminus of gp350, and soluble proteins containing 
the RBD (i.e. gp350FL, gp3501-470) could block EBV 
infection of B cells. Overall, these data show the 
importance of the RBD of gp350 as a target for 
neutralization and support the use of the gp350 RBD 
as a promising subunit vaccine candidate against 
EBV. 
Several approaches have been tested to develop 
an efficient vaccine candidate based on gp350 [9]. 
Soluble forms of the gp350 ectodomain expressed in 
CHO cells exhibited native conformation, bound the 
receptor CR2 and were recognized by several specific 
mAbs. The monomeric form of gp350 with native 
conformation induced high serum antibody titer that 
effectively neutralized EBV in vitro [24]. A truncated 
version of gp350 (gp3501-443), which contained the 
RBD, was produced from Pichia pastoris and induced 
high levels of specific antibodies and a strong T cell 
response in mice [25]. In addition, multimerization of 
gp350 antigens was shown to improve efficiency of 
vaccine candidates. Cui et al. demonstrated that a 
tetrameric gp3501-470 antigen induced higher 
neutralizing titer [26]. Recently, we showed that the 
dimeric antigen gp350ECD123 (amino acid 1-425, 
referring to the first three N-terminal domains) fused 
with immunoglobulin Fc fragments elicited a stronger 
humoral immune response in mice compared to the 
monomeric counterpart [27]. When expressed on 
self-assembling nanoparticles based on the ferritin 
protein, the gp350 RBD induced potent and durable 
neutralizing antibodies that prevented EBV infection 
in challenged mice [15]. VLPs based on Newcastle 
disease virus (NDV) matrix and nucleocapsid were 
engineered by fusing the gp350 ectodomain or RBD 
with the NDV F protein. These NDV-VLPs bound to 
CD21 and CD35 and elicited a long-lasting 
neutralizing antibody response in mice [28]. A cell 
line, HEK293-VII+, was engineered to produce 
EBV-derived VLP lacking viral DNA but presenting 
full-length gp350, gp140 and gp125 on their surface. 
These VLPs induced strong humoral response in a 
murine model in vivo and stimulated CD8+ and CD4+ 
T cell responses in vitro [29].  
Furthermore, nonhuman primates immunized 
with different gp350-based vaccine candidates were 
protected from EBV-induced lymphomas when 
challenged with native virus. Immunization with 
purified membrane containing gp350 (previously 
named gp340) or with recombinant gp350 could 
protect tamarins from EBV-induced diseases [30-33]. 
Recombinant vaccinia virus and replication defective 
adenovirus expressing gp340 effectively protected 
cottontop tamarins from EBV-induced malignant 
lymphomas [34-36].  
Recently, gp350-based candidate vaccines have 
been evaluated in human clinical trials. A vaccinia 





virus vector-based vaccine was tested in infants and 
all developed neutralizing antibodies [37]. In a phase I 
and I/II clinical trial, a recombinant subunit 
gp350-based vaccine elicited gp350-specific 
neutralizing antibodies [38]. In addition, recombinant 
gp350 adjuvanted with aluminum hydroxide and 
3-O-desacy-4’-monophosphory lipid A (AS04) 
efficiently prevented IM but did not prevent EBV 
acquisition in a cohort of seronegative individuals 
[39]. A gp350-based vaccine was also tested in 13 
children patients with chronic kidney disease. 
Neutralizing antibodies were detected in four 
recipients but the immune response declined rapidly 
[40]. These attempts highlight the benefits of gp350 
immunization but also the needs to improve 
immunogenicity and promote a long lasting immune 
response. 
Epitope peptides are considered to be valuable 
vaccine candidates, especially for conserved 
neutralizing epitopes [41, 42]. Several peptides 
derived from the gp350 RBD efficiently blocked CR2 
binding to EBV or to recombinant gp350 and could 
bind to CR2-positive B cells. Additionally, antibodies 
directed against these peptides inhibited EBV binding 
to B cells [43, 44]. 
Compared to full-length or truncated protein 
antigens, linear peptides do not present conformation- 
dependent epitopes. Although peptides allow 
targeting of precise functional domain, their 
conformational limitations may restrict the 
immunogenicity of peptide-based vaccines. The 
immunogenicity of epitope peptides with low 
molecular weights can be enhanced by 
multimerization [16] or by presentation of the 
peptides on the surface of recombinant VLPs. Here we 
used chimeric VLPs formed by the C-terminally 
truncated Hepatitis B virus core (HBc) protein (149 
aa), which have been considered as an ideal delivery 
vehicle for peptides derived from HIV, HCV, EV71, 
CA16, VZV, HEV, ZIKV and dengue virus [45-51]. 
Practically, chimeric HBc proteins produced in E.coli 
self-assemble and display foreign epitope peptides on 
the surface of VLPs [52, 53]. The region between 
amino acid 78 and 82 (MIR) is an ideal insertion site 
because it is surface accessible and not required for 
HBc self-assembly [54, 55]. In this study, we selected 
three peptides named P1 (aa 16-29), P2 (aa 142-161) 
and P3 (aa 282-301) from the gp350 RBD and used the 
truncated HBc149 as an immune carrier. The three 
peptides were inserted into the MIR of HBc149 in 
different tandem order combinations. All five 
constructs yielded well-formed spherical particles. 
Interestingly, different arrangements of the three 
epitopes greatly influenced the humoral response of 
immunized mice. Two configurations, 149-3A 
(P1P2P3) and 149-3B (P1P3P2) elicited high antibody 
titers against gp350ECD123 (corresponding to 
gp3501-425), while other combinations were poorly 
immunogenic. In addition, sera collected from 149-3A 
and 149-3B immunized mice showed high 
competitive activity with a neutralizing mAb 72A1, 
thereby indicating the presence of Abs against a major 
neutralizing epitope of gp350. More importantly, sera 
from 149-3A and 149-3B-immunized mice neutralized 
EBV infection of cells in vitro. Altogether these data 
support the use of HBc-VLPs as useful vectors for 
gp350 peptides to induce anti-EBV neutralizing 
antibodies. 
Materials and Methods 
Plasmids Construction for Expression of 
Recombinant HBc149-based Fusion Proteins 
Plasmid pET-28a-HBc149 was constructed as 
previously reported [56]. Briefly, the encoding 
sequence of HBc149 was inserted into the vector 
pET-28a between the restriction endonuclease sites of 
Nde I and Hind III. Amino-acids 79-81 were replaced 
by GGGGSGGGGT-GS-EF-GGGGSGGGGS in which 
GS was coded by a BamH I site and EF was coded by 
an EcoR I site. The combination sequences coding for 
the gp350 peptides were synthesized (Beijing Ruibio 
Biotech Co., Ltd) and inserted into the linearized 
vector. The five combinations were: P1-L-P2-L-P3 
(3A), where L represents the G4SG4S linker, 
P1-L-P3-L-P2 (3B), P2-L-P1-L-P3 (3C), P2-L-P3-L-P1 
(3D) and P3-L-P2-L-P1 (3E). The fusion clones were 
confirmed by sequencing and the five constructions 
were named 149-3A, 149-3B, 149-3C, 149-3D and 
149-3E respectively. The wide-type HBc149 vector 
was used as a control. 
Protein Expression and Purification 
Plasmids coding the various constructs were 
transformed into BL21 (DE3) competent bacteria. 
Positive clones were selected and amplified in liquid 
cultures. Then, 5 ml of fresh overnight cultures were 
inoculated into 500 ml fresh LB medium in the 
presence of 100 mg/L kanamycin at 37°C. Proteins 
production was induced by adding IPTG to a final 
concentration of 0.5 mM at 30°C for 6-8 h when 
OD600=0.8. 
The harvested bacterial pellets were 
resuspended in PBS (pH 7.4). After ultrasonication 
and high speed centrifugation (25000 x g, 30 min), the 
supernatants were collected and precipitated using 
30% saturated ammonium sulfate. The precipitated 
material was resuspended in PBS and dialyzed 
against PBS. The proteins were further purified by gel 
filtration using superpose 6 increase 10/300 GL 





columns (GE). The concentration of the target proteins 
were determined using BCA assay. The purified 
proteins were stored at -80°C prior to use. 
SDS-PAGE and Western blotting (WB) 
The protein samples were subjected to 12% 
SDS-PAGE gels for 1 h at 160 V and the total proteins 
were visualized by coomassie brilliant blue staining. 
For WB, after SDS-PAGE, proteins were 
transferred onto polyvinylidene fluoride membranes 
(Millipore). The membranes were blocked with 5% 
skim milk in TBST buffer (25 mM Tris, 250 mM NaCl, 
0.1% Triton-20, pH 7.4) for 2 h at room temperature. 
To detect the HBc149 antigen, mAb 11H10 (gift from 
Prof. Xia of Xiamen University) was used (1:2,000 
dilution). For detection of gp350 epitopes, an 
antiserum prepared in our lab was used (1:1,000 
dilution). The membranes were inoculated with 
diluted antibodies at 4°C overnight. After three 
washes with TBST, membranes were incubated with a 
secondary goat anti-mouse antibody (1:10,000, 
Promega) conjugated with horseradish peroxidase 
(HRP) for 1 h at room temperature. ECL substrate was 
used for detection (Advansta). 
Transmission Electron Microscopy (TEM) 
The recombinant proteins were analyzed by 
negative staining electron microscopy. Briefly, protein 
samples were diluted to 0.5 mg/ml and applied to 
200-mesh carbon-coated copper grids for 5 min. 
Excessive solution was removed, grids were washed 
twice with double distilled water and then 
immediately negatively stained for 30 s with freshly 
filtered 2% phosphotungstic acid (pH 6.4). Grids were 
examined with a FEI Tecnai T12 TEM (FEI, USA) at an 
accelerating voltage of 120 kV and photographed at a 
magnification of 25,000 fold. 
High Performance Size Exclusion 
Chromatography (HPSEC) 
All purified proteins were analyzed using a 1120 
Compact LC HPLC system (Agilent Technologies; 
Santa Clara, CA) and separately with a TSK Gel 
PW5000xl 7.8 mm × 300 mm column (TOSOH, Japan); 
columns were pre-equilibrated in PBS. The column 
flow rate and protein signal detection for the SEC 
analysis were 0.5 ml/min and 280 nm. 
Indirect Enzyme-Linked Immunosorbent 
Assay (ELISA) 
Purified gp3501-425-His was coated on 96-well 
microplates (Corning) (100 ng/well in PBS) for 2 h at 
37°C. The plates were washed once and then blocked 
with blocking buffer (PBS pH 7.4, containing 2% 
gelatin, 0.5% casein and 0.1% ProClin 300) overnight 
at 4°C. Then, 5-fold serial dilutions of sera were added 
to the plates and incubated for 1 h at 37°C. The plates 
were washed 5 times and incubated for 30 min at 37°C 
with 100 μl of horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgG (Promega) 
(1:20,000 dilution). Signals were developed using 
EL-TMB kit (Sangon Biotech). Absorbance was 
measured at 450 nm using a microplate reader 
(Molecular Devices). The cutoff value was set to 0.1 
which was determined by the OD450 value of 
preimmune sera. 
Competitive Enzyme-Linked Immunosorbent 
Assay (ELISA) 
MAb 72A1 (ATCC cell line ID: HB168) 
conjugated with HRP was used in this assay. First, 
2-fold dilutions of 72A1-HRP were used to determine 
the OD450 for binding to gp3501-425-His coated on the 
plates (100 ng/well). A 1.0 value for OD450 was 
arbitrarily selected for competition assays and 
corresponds to a 1:25,600 dilution. Second, in 
competition assay, 2-fold serially diluted sera 
(starting from 1:5) were added to the gp3501-425-His 
coated plates and incubated for 1 h at 37°C. Then 
72A1-HRP (1:25,600 dilution) was added to the plates 
after 5 TBST wash and incubated for 30 min at 37°C. 
Bound HRP activity was detected using the EL-TMB 
kit (Sangon Biotech). The competitive ability of the 
sera samples against 72A1 was calculated using the 
following equation: Percentage of inhibition 
%=[OD(-serum/+72A1)-OD(+serum/+72A1)]/ OD(-serum/+72A1) x 
100. 
Mouse Immunization Assay 
Five female special pathogen free (SPF) female 
BALB/C mice (6-8 weeks) per group were immunized 
subcutaneously (s.c.). The proteins were formulated 
with aluminum hydroxide so that each dose 
contained 20 μg purified proteins. One primary 
injection dose and two booster doses were given at 
two week intervals (week 0, 2, 4). The immunized 
mice were bled at weeks 0 (preimmune), 1, 2, 3, 4, 5, 6, 
8, 10 and14 for serological tests. All collected sera 
were stored at -20°C prior to use. 
Infection Blocking Assay 
The EBV infection assay was performed as 
previously reported [20]. AKATA-EBV-GFP was 
produced in CNE2-EBV cells [57]. Representative 
mAb 72A1 or 2-fold serial diluted sera (starting from 
1:2) were incubated with 100 μl virus stock in 1.5 ml 
tubes for 2 h at 37°C. Subsequently, the mixture of 
mAb or sera with EBV were added to105 AKATA 
negative cells (no latent EBV) at 37°C for 3 h. After 
incubation, the cells were pelleted by centrifugation 
and washed once using PBS before being cultured in 
RPM1640 with 10% FBS in 24-well plates for 48 h. The 





cells were then collected and washed once with PBS. 
The EBV infection rate was determined by measuring 
the production of GFP expressing cells by flow 
cytometry. In this assay, uninfected cells were used as 
negative controls and AKATA negative cells 
incubated with EBV in the absence of antibodies were 
used as positive controls. 
Homology Modeling 
The crystal structures of gp350ECD123 (PDB no. 
2H6O) and HBc149 (PDB no. 1QGT) were used as 
templates for homology modeling of the chimeric 
monomers. After sequence alignment with the 
respective chimeric sequences, the initial 3D models 
were generated using the Homology module of 
Discovery Studio 2.5 program (Accelrys). HBc149 
(PDB no. 1QGT) VLP template was utilized to 
generate the complete chimeric VLP models. Stepwise 
minimizations were subsequently implemented to the 
peptides insertion site of each model to achieve 
thermodynamically favored conformations. 
Statistics 
All statistical analyses were carried out with 
GraphPad Prism version 5. p-Values were generated 
by one-way ANOVA analysis. p-Values of ≤0.05 were 
considered to be statistically significant. 
Results 
Rational molecular design of fusion proteins 
In this study, a C-terminal truncated HBc protein 
(aa 1-149, HBc149) was used as a carrier protein to 
enhance the immunogenicity of gp350 RBD epitope 
peptides. The HBc149 protein was modified and 
amino acids 79-81 were substituted with 
GGGGSGGGGTGSEFGGGGSGGGGS to provide an 
insertion site flanked by flexible G4SG4S linkers (Fig. 
1A). This allows for the insertion of foreign epitope 
peptides in a site exposed at the surface of VLPs. The 
crystal structure of gp350ECD123 has been 
determined and the receptor-binding domain was 
identified by mutagenesis [22]. Three linear peptides 
that form part of the RBD at the surface of gp350 were 
selected (Fig. 1B). Sequences of these peptides was 
aligned using MEGA 5.05 and Weblogo programs. 
The alignments showed high levels of conservation of 
all three peptides among 32 EBV gp350 sequences 
from Genebank (Fig. 1C). We designed five different 
arrangements of three peptides (149-P1/P2/P3, 
149-P1/P3/P2, 149-P2/P1/P3, 149-P2/P3/P1 and 
149-P3/P2/P1) and the corresponding fusion proteins 
were named 149-3A, 149-3B, 149-3C, 149-3D and 
149-3E respectively (Fig. 1D). The unmodified HBc149 
(wild-type) and soluble gp350ECD123 [27] were used 
as controls in subsequent assays. 
Expression and characterization of fusion 
proteins 
All the fusion proteins were expressed in BL21 
(DE3) bacteria. Analysis of HPSEC purified proteins 
by SDS-PAGE shows high purity and homogeneity of 
each product (Fig. 2A). In addition, mAb 11H10 
against HBc149 and antisera against gp350ECD123 
recognized the fusion proteins in WB assay (Fig.2B 
and 2C). 
Particle profiles were analyzed using 
negative-stained TEM and HPSEC (Fig. 3). The results 
showed that all the fusion proteins self-assembled 
into particles of similar sizes and morphologies. The 
inserted peptides in various orders did not have a 
detectable effect on the folding and self-assembly of 
chimeric HBc149 VLPs. 
Immunogenicity of the chimeric VLPs 
To assess the immunogenicity of the chimeric 
VLP, BALB/c mice (n=5 per group) were inoculated 
three times at 2-week intervals with chimeric VLPs 
(Fig. 4A). The antigens were formulated with 
aluminum adjuvant using 20 μg proteins at each 
injection. Serum was collected over 14 weeks and 
antibody titer against soluble gp350ECD123 was 
determined by ELISA. VLPs 149-3A and 149-3B 
elicited higher antibody titer than soluble 
gp350ECD123 controls (Fig. 4B). The sera titer 
increased to about 5-log for 149-3B and 4.5-log for 
149-3A in comparison with 4-log for gp350ECD123 at 
1 week after the third injection (week 5). The peak 
titers of approximately 6-log for 149-3B and 5-log for 
149-3A (4.5-log for gp350ECD123) were measured at 8 
weeks, and the sera titer were maintained at 4.5-log 
for 149-3A and 149-3B for at least 14 weeks after the 
first immunization. The data demonstrated that 
selected gp350 peptides presented on 149-3B and 
149-3A VLPs can induce higher anti-gp350 antibody 
titers than the monomeric gp350ECD123 protein (Fig. 
4B). 
Surprisingly, the other three fusion proteins, 
149-3C, 149-3D and 149-3E did not induce comparable 
sera titer, suggesting that the order of gp350 peptides 
in HBc149 constructs is critical for immunogenicity of 
VLPs. To confirm that all VLPs were equally injected 
during immunization, the binding activity of immune 
sera to HBc149 was tested (Fig. 4C). There was no 
significant difference of antibody titers against 
HBc149 for the five fusion proteins and the HBc149 
positive control (Fig. 4C). Because VLPs were 
generated in bacteria and gp350ECD123 was 
produced in insect cells, it could be possible that the 
immunogenicity of VLPs was artificially enhanced by 
an adjuvant effect due to contamination with high 
amounts of lipopolysaccharides (LPS). We therefore 





quantified the levels of endotoxin in the protein 
samples that were used for immunization. There was 
no difference in endotoxin content between samples 
of the various VLPs, and these levels were not 
different from levels in the insect cell-produces 
gp350ECD sample (Figure S1). These data indicate 
that an adjuvant effect of LPS endotoxin contaminants 
is not responsible for the difference in 
immunogenicity observed in our in vivo experiments. 
Overall, our data show that all groups received 
similar amounts of purified VLP antigens and that the 
difference of anti-gp350 titers observed between 
constructs is due to the presentation of peptides on 
VLPs. 
Chimeric VLPs (149-3A and 149-3B) induced 
potent production of neutralizing antibodies 
To determine whether VLP’s elicited antibodies 
against a major neutralizing epitope of gp350, 
immunized sera were evaluated using a competition 
ELISA [27]. The mAb 72A1, is a strong neutralizing 
antibody against EBV infection into B cells that binds 
to the gp350 RBD [22, 23]. To assess the presence of 
serum antibodies against the same neutralizing 
 
 
Fig. 1. Schematic diagram of the rational design and peptides combination vaccine candidates. (A) Truncated HBV core protein (HBc149) was engineered for 
convenient presentation of foreign epitopes. (B) The crystal structure of the gp350 N-terminal (PDB no. 2H6O) is shown as a surface model. The selected three peptides are 
colored with yellow (peptide 1, P1), brown (peptide 2, P2) and cyan (peptide 3, P3). The receptor binding domain is circled in purple. (C) Sequence alignment of P1, P2 and P3 
peptides using 32 independent sequences from genebank. The sequence logos were generated using weblogo (http://weblogo.berkeley.edu/). Numbers, on the y-axis, represent 
the total sequences used in this alignment. (D) Schematic representation of the different constructs. Epitope peptides P1, P2, P3 were inserted into the modified HBc149 vector 
in different orders linked with GGGGSGGGGS linker (L). 





epitope, we used a competition ELISA against mAb 
72A1. First, we established a binding curve for mAb 
72A1-HRP to gp350ECD123 (Fig. 5A). The dilution 
fold of 1:25,600 for 72A1-HRP corresponds to a value 
of 1.0 OD450 and was selected for competition assays. 
In competition assays, serially diluted sera were used 
to inhibit binding of 72A1-HRP to gp350ECD123. A 
decreased binding of mAb 72A1-HRP indicates the 
presence of competing antibodies, presumably to the 
same epitope, in immune sera. The results indicated 
that sera from mice injected with 149-3A and 149-3B 
showed better competition compared to sera from 
mice immunized with gp350ECD123 (Fig. 5B). At 
5-fold and 10-fold dilution, the sera inhibited more 
than 50% binding of 72A1-HRP. As expected, low titer 
sera from mice immunized with 149-3C, 3D and 3E 
did not efficiently compete with mAb 72A1 binding. 
Sera from mice immunized with control HBc149 alone 
show a constant background of inhibition, consistent 
with previous studies [27, 58]. This competition assay 
demonstrates that peptides displayed on HBc-VLPs in 
defined orders elicit a potent antibody response 
against gp350. Furthermore, competition data showed 
that these antibodies detect epitopes which overlap 
with the major neutralizing epitope recognized by 
mAb 72A1. 
To confirm that serum antibodies have a 
functional neutralizing activity, an in vitro 
neutralization assay was used to evaluate the 
efficiency of sera in blocking EBV infection of AKATA 
cells. To set up the neutralizing assay, mAb 72A1 was 
used as a positive control. In the absence of 
antibodies, about 20% of cells were infected by the 
EBV-GFP reporter virus. In this assay, the IC50 for 
mAb 72A1 was 10.9 μg/ml (Fig. 6A). Serially diluted 
sera collected at eight weeks were used. Sera from 
mice immunized with 149-3A and 149-3B showed 
stronger neutralizing efficiency compared to the sera 
raised against soluble gp350ECD123. At 2-fold, 4-fold 
and 8-fold dilutions, the sera raised against 149-3A 
and 149-3B showed over 50% neutralizing efficiency 
against EBV infection. The corresponding ID50 values 
are 13.43 and 18.93 for sera from animals immunized 
by 149-3A and 149-3B respectively (Table S1). 
(Reviewer 3, point 4) Other constructs only show 
limited neutralization, close to non-specific activity 
and their ID50 values could not be reliably 
determined. 
To better quantify the efficacy of the different 
antigens, sera collected at ten weeks were tested in 
this neutralization assay at a 10-fold dilution. Here 
again, sera collected from mice immunized with 
149-3A and 149-3B blocked EBV infection of AKATA 
cells most efficiently (Fig. 6C). Importantly, the 
neutralization titers induced by 149-3B and 149-3A 
were significantly higher than that of the other fusion 
proteins and the monomeric gp350ECD123. This 
monomer is partially glycosylated in insect cells and 
can elicit conformation-dependent antibodies. In 
contrast, the fusion proteins 149-3A and 149-3B that 
were expressed in bacteria and contained linear gp350 
peptides that lack glycosylation sites, induced a more 
potent neutralization response. 
 
 
Fig. 2. Analysis of the E.coli-expressed HBc149 fusion proteins by 
SDS-PAGE. (A) SDS-PAGE analysis of the purified fusion proteins stained by 
coomassie brilliant blue. (B) Western blot analysis of fusion proteins with 
anti-HBc149 mAb 11H10. (C) Western blot analysis of fusion proteins with serum 
anti-gp350ECD123. 
 
In order to confirm that sera 149-3A and 149-3B 
detect gp350 in EBV producing cells, we performed 





IFA staining of AKATA-EBV stimulated cells. In this 
assay, the same staining pattern was observed for the 
mAb 72A1 and the two neutralizing sera (data not 
shown). 
In summary, the designed fusion proteins 
formed chimeric VLPs with different peptides 
combinations. The specific arrangement of three 
gp350 peptides on 149-3A and 149-3B VLPs generated 
higher anti-gp350 antibody titers compared to the 
subunit gp350ECD123 antigen. The sera collected 
from 149-3A and 149-3B VLPs immunized mice 
shared overlapped epitopes with mAb72A1 and 
neutralized EBV infection of B cells. 
 
 
Fig. 3. Characterization of self-assembly of the fusion proteins into VLPs. (A) TEM images of suspensions of VLPs (magnification: 25,000x). Scale bars represent 100 
nm. (B) Analysis of VLPs by HPSEC. Elution profiles (arbitrary units over time) show that all preparations are highly homogenous. The peak elution time is indicated.  






Fig. 4. Immunogenicity of the purified fusion proteins. (A) Immunization procedure. Immunization (white triangles) and bleeding time points are shown (red drops). (B) 
Anti-gp350 titers determination by ELISA. gp350ECD123 was immobilized on 96-well plates and the diluted sera were added for titers determination. The OD450=0.1 was set 
as the cut-off value. Significance (*p≤0.05, **p≤0.01, ***p≤0.001) between 149-3A and 149-3B VLPs versus gp350ECD123 is shown. Both constructs 149-3A and 149-3B have the 
same level of significance above gp350ECD123. (C) Binding titers of serum antibodies to the vector (HBc149) collected after eight weeks. The error bars indicated the standard 
deviation in each group (n=5 mice). 
 
Discussion 
Vaccination is proven to be safe and 
cost-effective way to protect against pathogen 
infections and relevant infectious diseases. To date, 
there is no prophylactic vaccine for clinical use against 
EBV. Different subunit vaccines have been developed 
based on dimeric, tetrameric and polymeric forms of 
gp350 which elicited potent neutralizing antibodies 
and cytokine responses [15, 26, 27]. Here we 
considered peptide-based approach as an attractive 
alternative strategy to direct the antibody response 
against a neutralizing site of gp350. The N-terminus 
fragment gp3501-425 retains the complete binding 
activity with the receptor CR2. Therefore, peptides 
localized to this region are ideal candidates for a 
rational design of EBV vaccines. 






Fig. 5. Blocking the binding of the neutralizing mAb 72A1 to gp350ECD123 in a competition ELISA. (A) Binding of mAb 72A1-HRP to immobilized 
gp350ECD123. Serial dilutions of antibody were used to determine the dilution factor corresponding OD450=1.0. (B) Binding of mAb 72A1-HRP to immobilized gp350ECD123 
is competed by the indicated immune sera. Serial dilution of sera were applied to gp350ECD123 before the addition of mAb 72A1-HRP in this competition ELISA. Data are shown 
as % inhibition of mAb 72A1binding. High inhibition indicates the presence of competing antibodies in the tested sera. Significance (*p≤0.05, **p≤0.01, ***p≤0.001) is indicated for 
149-3A and 149-3B VLPs compared to gp350ECD123. Both constructs 149-3A and 149-3B have the same level of significance above gp350ECD123. 
 
In our study, we selected three peptides that 
were previously identified by structural modeling, 
functional tests, and mutagenesis. The peptide 
corresponding to the N-terminus of gp350 (aa 16-29, 
IHLTGEDPGFFNVE) binds to CR2, inhibits CR2 
binding to immobilized EBV and blocks recombinant 
gp350 binding to B cells [43]. The other two peptides 
(aa 142-161, HHAEMQNPVYLIPETVPYIK and aa 
282-301, YVFYSGNGPKASGGDYCIQS) are involved 
in EBV binding to B cells and inhibit mAb 72A1 
binding to EBV [44]. In addition, sera collected from 
rabbits immunized with these peptides contained 
anti-peptide antibody titers between 6,400 and 51,200 
and slightly lower antibody titer against EBV 
(between 3,200 and 25,600) [44]. The functional 
importance of these regions was confirmed by 
mutagenesis. Key residues (Glu21, Asp22, Tyr151, Glu155, 
Ile160, Trp162, Asp208, Glu210 and Asp296) are located at 
the interface between gp350 and CR2 [59]. X-ray 
crystallography further identified three discontinuous 
peptides at the interface corresponding to 
Pro158Tyr159Ile160, Trp162Asp163Asn164 and Asp208Glu210 
[22]. All the findings paved the way for rational 
design of epitope peptides-based vaccine against EBV. 
Often, one peptide epitope may not be sufficient 
to induce strong enough immune responses against 
viral infection. In this study, three epitope peptides 
were simultaneously displayed on the surface of 
chimeric VLP with ‘G4SG4S’ as a linker between them. 
Our study demonstrated the potential of the chimeric 
149-3B and 149-3A combinations to generate 
immunogenic VLPs. Interestingly, for 149-3C, 149-3D 
and149-3E constructs, the orders of these epitopes 
affected the immunogenicity and the neutralizing 
activity of sera, but did not appear to influence 
assembly of the chimeric VLPs. Figure 7 shows 
structural models of the different fusion proteins and 
VLPs. Interestingly, the presentation of the peptides 
varies considerably between VLPs. Since the peptides 
are arranged in the same linear fashion but in 
different order (Fig. 1D), the structural variability is 
caused by the composition and folding of each 
peptide and the flexibility that each combination 
allows. The models of 149-3A and 149-3B suggest 





more flexible conformations of the peptides compared 
to 149-3C, 3D and 3E. This may allow 149-3A and 
149-3B VLPs to generate stronger neutralizing 




Fig. 6. Neutralizing of EBV infection. (A) Neutralizing curve for mAb 72A1 against EBV-GFP infection of AKATA cells. M Ab 72A1 was used to validate the neutralization 
assay and its IC50 is indicated. (B) Neutralization of infection by immune sera. Serially diluted sera collected at week 8 were used to block EBV infection of AKATA cells. 
Significance (*p≤0.05, **p≤0.01, ***p≤0.001) is indicated for 149-3Aand 149-3B VLPs compared to gp350ECD123. Both constructs 149-3A and 149-3B have the same level of 
significance above gp350ECD123. (C) Sera collected at week 10 was diluted 10 fold to block EBV infection into AKATA cells (n=5). Significance (*p≤0.05, **p≤0.01, ***p≤0.001) 
between the indicated fusion proteins versus gp350ECD123 is shown. EBV-GFP show the level in the absence of inhibitors. Neg shows the background level in the absence of 
infection. 72A1 shows the level of inhibition by mAb 72A1 at 50 μg/ml.  






Fig. 7. Models of fusion proteins and chimeric VLPs corresponding to different constructs. The left, middle and right panels show structural models for monomers 
(ribbon), dimers (surface) and chimeric VLPs (surface) of fusion proteins. Homology structural modeling of the recombinant fusion proteins and chimeric VLPs were implemented 
using MODELER module of Accelrys Discovery Studio 2.5. All illustrative models were prepared using PyMol. The three peptides are colored with yellow (peptide 1, P1), brown 
(peptide 2, P2) and cyan (peptide 3, P3). The peptide insertion site on HBc149 is shown in purple on the wild-type protein and VLP. 
 
Soluble monomeric gp350 is a relatively poor 
antigen, which immunogenicity is increased by about 
20-fold through tetramerization [26, 60]. We also 
previously showed increased immunogenicity 
through dimerization of gp350ECD123 [27]. Several 
other approaches with full-length or truncated gp350 
showed superior immunogenicity and ability to 
induce neutralizing antibodies [60]. Peptide antigens 





do not elicit antibodies against conformation- 
dependent epitopes, thus linear peptides often have 
reduced immunogenicity compared to proteins. 
Despite this intrinsic shortcoming, our selection of 
three peptides from a functional site on gp350 
induced a better neutralization response than 
monomeric gp350ECD123. Nevertheless, our data 
reveal some limitation of the use of peptides, notably 
the effect of the positioning of the peptides on 
HBc-149 VLPs. Although peptide antigens offer the 
advantage of combining several targeted epitopes, the 
presentation of peptide antigen in VLPs need further 
improvement to reach the immunogenicity level of 
protein multimers. 
Many factors can affect the success of 
peptide-based vaccines, our data highlight the 
importance of the order of epitopes when designing 
vaccines based on multiple epitopes. In addition to 
peptide display, VLPs, may affect epitope 
immunogenicity due to their own physical properties 
(e.g. posttranslational modifications, aggregation, 
solubility, intrinsic immunogenicity). Our data show 
that in the presence of aluminum hydroxide adjuvant, 
VLPs with peptide antigens performed better than the 
soluble protein antigen in eliciting neutralizing 
antibodies. Different adjuvants could help to further 
enhance the immunogenicity of chimeric VLPs [49]. 
In previous studies, gp350 was used as the major 
immunogen for vaccine development, although it is 
only effective in preventing infection of B cells. 
However, EBV encodes at least thirteen envelope 
glycoproteins that could be considered in vaccine 
design [61, 62]. In particular, glycoproteins involved 
in the viral fusion apparatus (gL/gH, gp42 and gB) 
have become very promising targets for the 
development of prophylactic vaccines. Immunization 
with nanoparticles or multimeric forms of these 
glyproteins elicited robust neutralizing antibodies 
able to protect B cells as well as epithelial cells [13-15, 
60]. Indeed, potent neutralizing epitopes were 
localized on gH/gL, gB and gp42 [63, 64]. Antibodies 
raised against three epitope peptides derived from gH 
could inhibit the interaction between EBV and cord 
blood lymphocytes [63]. Additional peptide epitopes 
identified in silico and in functional assays also 
warrant further functional investigation [64-67]. 
Several CTL epitopes were identified in gp350 and, 
interestingly, among the peptides that bound 
HLA-A2, the LIPETVPYI peptide is contained within 
peptide P2 used in the present study [65]. However 
this peptide failed to efficiently stimulate CTL 
effectors from IM donors ex vivo [65]. In that study, a 
more distant gp350 peptide (VLQWASLAV, aa 
863-871) was able to induce a functional CTL response 
ex vivo and in HLA-A2 transgenic mice, which became 
protected against a gp350-expressing recombinant 
vaccinia virus [65]. Linear CD4 T-cell epitopes were 
also identified in gp350 (incl. aa 65-75, 
FGQLTPHTKAV and aa 163-183, DNCNSTNITAVVR 
AQGLDVTL) [66]. Therefore, future designs of 
peptide vaccines will successfully include various 
epitopes from different antigens and integrate B and T 
cell epitopes into one antigenic formulation [9, 60]. 
VLPs based on HBc149 provide an appropriate 
platform to engineer complex peptide-based epitopes. 
Our study opens the possibility to develop 
pluripotent vaccines by combining HBc149-derived 
VLPs engineered to express B and T cell peptide 
epitopes from different EBV glycoproteins. 
This work provides encouraging results towards 
the design of novel EBV vaccine candidates on the 
basis of HBc protein mosaic VLPs that display epitope 
peptides derived from gp350. More generally, our 
data provide proof of principle for EBV vaccine 
design combining multiple antigenic epitopes on 
HBc149 VLPs. A multi-peptide strategy that includes 
epitopes from the fusion machinery (gL, gH, gp42 and 
gB) in addition to gp350 will further enhance the 
efficacy of VLPs as vaccines against EBV. 
Conclusion 
Three epitopes among different strains derived 
from the receptor binding domain of EBV envelope 
protein gp350 were combined to be displayed on the 
surface of chimeric HBc149 VLPs. These well-formed 
spherical bionanoparticles were characterized by a 
combination of physico-chemical methods. Among 
these five VLPs, 149-3A and 149-3B showed higher 
immunogenicity compared to purified gp350ECD123. 
More importantly, these two particles induced 
stronger neutralizing antibodies in mice to block EBV 
infection in a cell model. Therefore, different 
combinations of epitopes could affect the overall 
immune response. Consequently, HBc149-based 
chimeric VLPs provided an effective platform for the 
development of novel peptide-based candidate 
vaccines against EBV. 
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